<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lathyrism has been reviewed in respect to four overlapping phases: finding an animal model for neurolathyrism, characterizing osteolathyrism in respect to its possible use as an animal model for human diseases, such as <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e>, idiopathic juvenile <z:hpo ids='HP_0002650'>scoliosis</z:hpo>, etc., use of <z:chebi fb="0" ids="27413">beta-aminopropionitrile</z:chebi> (<z:chebi fb="0" ids="27413">BAPN</z:chebi>) as a tool to study collagen, and use of <z:chebi fb="0" ids="27413">BAPN</z:chebi> as a therapeutic agent in man </plain></SENT>
<SENT sid="1" pm="."><plain>Because it has been suggested that the lathyrogen, <z:chebi fb="0" ids="27413">BAPN</z:chebi>, may stimulate the release of proteases, the <z:chebi fb="0" ids="37670">protease inhibitors</z:chebi> Trasylol and <z:chebi fb="0" ids="16586">epsilon-aminocaproic acid</z:chebi> (<z:chebi fb="0" ids="16586">EACA</z:chebi>) were given alone or in combination to <z:chebi fb="0" ids="27413">BAPN</z:chebi>-treated rats </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:chebi fb="0" ids="37670">protease inhibitors</z:chebi> did not reduce the effects of <z:chebi fb="0" ids="27413">BAPN</z:chebi> as measured by <z:mp ids='MP_0009877'>exostosis</z:mp> formation or collagen extractability </plain></SENT>
</text></document>